Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Seres Therapeutics (MCRB) PT Lowered to $16 at Oppenheimer
November 9, 2018 8:57 AM ESTOppenheimer analyst Mark Breidenbach lowered the price target on Seres Therapeutics (NASDAQ: MCRB) to $16.00 (from $17.00) while maintaining a Outperform rating.
The analyst commented, "Thursday, Seres reported 3Q results and reviewed recent progress. With the appointment of a new CMO, we see... More
Seres Therapeutics (MCRB) Misses Q3 EPS by 2c, Revenues Miss
November 8, 2018 7:13 AM ESTSeres Therapeutics (NASDAQ: MCRB) reported Q3 EPS of ($0.54), $0.02 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $9 million versus the consensus estimate of $11.37 million.
Based on a growing body of promising clinical data and preclinical data from our... More
